Skip to main content

Solid Biosciences Inc.

SLDB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001707502

No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Solid Biosciences Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of SLDB: Q3 2022 compared with Q4 2022
MeasureQ3 2022Of which not filed for Q4 2022Q4 2022Change
Holders58135−22
SharesConverted for a 1-for-15 split4.24M615.3M+11.1M (+261.5%)
Value$33.4M$0$85.6M+$52.2M (+156.4%)

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (7)

Institutions that held Solid Biosciences Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to SLDB in Q4 2022
InstitutionSharesValue% of portfolio
Camber Capital Management LP1,418,439$7.63M0.27%
Caas Capital Management LP283,687$4.81M0.93%
Finepoint Capital LP218,562$1.18M0.38%
Dimensional Fund Advisors LP55,738$300.0K0.00%
Old Well Partners, LLC10,800$58.1K0.05%
Belpointe Asset Management LLC1,367$7.35K0.00%
Manchester Capital Management LLC1,000$5.38K0.00%

Sold out (29)

Institutions that held Solid Biosciences Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Not filed for Q4 2022 yet (1)

Institutions that held Solid Biosciences Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SLDB in Q3 2022 that haven't filed for Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Corsicana & Co.90–